Literature DB >> 31696367

Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer.

P Widschwendter1, W Janni2, C Scholz2, A De Gregorio2, N De Gregorio2, T W P Friedl2.   

Abstract

PURPOSE: Lymph node metastases significantly worsen the prognosis in cervical carcinoma. Risk factors-pathological and patient related-could select patients at high risk for lymph node involvement.
METHODS: This retrospective analysis was performed by analyzing data from patients with cervical carcinoma treated between 2000 and 2017 at the Department of Obstetrics and Gynecology of the University Hospital Ulm.
RESULTS: In total, 261 patients with cervical carcinoma (International Federation of Gynecology and Obstetrics (FIGO) stage IA-IIB) and lymphadenectomy with at least 10 removed lymph nodes were available for analysis. Overall, 86 (33.0%) patients had lymph node metastases; 73 patients had pelvic lymph node metastases only and 13 patients had both pelvic and paraaortic lymph node metastases. Lymph node metastases were found most often in the region of the external iliac artery and obturator fossa, with 57.0% and 54.7% of all 86 node-positive patients, respectively. Univariable analyses showed that presence of lymph node metastases was significantly associated with both preoperative FIGO stage (p = 0.001) and final pathological tumor stage (p < 0.001), status of resection margin (p = 0.002), lymphovascular space invasion (LVSI), (p < 0.001) and vascular space invasion, (p < 0.001). In a multivariable logistic regression model with presence of lymph node metastases (yes/no) as binary response variable, only LVSI (p < 0.001) and body mass index (BMI), (p = 0.035) remained as significant independent predictors of lymph node involvement. Subgroup analyses showed that LVSI was a significant predictive factor for lymph node involvement in patients with a preoperatively assessed FIGO stage < IIB (p < 0.001), but not for patients with a preoperatively assessed FIGO stage ≥ IIB (p = 0.122).
CONCLUSIONS: The risk factor LVSI should play an important role in deciding whether an individualized therapy concept is based on escalating or deescalating treatment. In future, the sentinel concept could reduce morbidity and at the same time provide an important prognostic assessment for a subset of cervical cancer patients.

Entities:  

Keywords:  Cervical cancer; LVSI; Lymph node; Pattern; Prognostic factor

Year:  2019        PMID: 31696367     DOI: 10.1007/s00404-019-05341-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  4 in total

1.  Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Authors:  Innocenza Palaia; Federica Tomao; Anna DI Pinto; Angelina Pernazza; Giusi Santangelo; Nicoletta D'Alessandris; Lucia Manganaro; Antonio Arno; Violante DI Donato; Giorgia Perniola; Carlo Della Rocca; Pierluigi Benedetti Panici
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

2.  Circular RNA circNRIP1 promotes migration and invasion in cervical cancer by sponging miR-629-3p and regulating the PTP4A1/ERK1/2 pathway.

Authors:  Xinhui Li; Ningye Ma; Yao Zhang; Heng Wei; Huijie Zhang; Xiaoao Pang; Xiang Li; Dan Wu; Dian Wang; Zhuo Yang; Shulan Zhang
Journal:  Cell Death Dis       Date:  2020-05-26       Impact factor: 8.469

3.  The diagnostic value of core needle biopsy in cervical cancer: A retrospective analysis.

Authors:  Massimiliano Lia; Lars-Christian Horn; Paulina Sodeikat; Michael Höckel; Bahriye Aktas; Benjamin Wolf
Journal:  PLoS One       Date:  2022-01-05       Impact factor: 3.240

4.  Does the New FIGO 2018 Staging System Allow Better Prognostic Differentiation in Early Stage Cervical Cancer? A Dutch Nationwide Cohort Study.

Authors:  Mieke L G Ten Eikelder; Floor Hinten; Anke Smits; Maaike A Van der Aa; Ruud L M Bekkers; Joanna IntHout; Hans H B Wenzel; Petra L M Zusterzeel
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.